Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B study
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Quantitative Southern blot analysis of blood samples may be substituted for bone marrow to monitor the response to therapy in CML and results in the need for fewer bone marrow examinations. To avoid overestimating the degree of response, marrow cytogenetic analysis should be performed when patients achieve a complete response by Southern blot monitoring. This approach provides a rational, cost-effective strategy to monitor the effect of treatment of individual patients, as well as to analyze large clinical trials in CML.